In a striking turn of events, Shivinder Mohan Singh, once a prominent figure in India’s healthcare and pharmaceutical landscape, has filed for personal insolvency under Section 94 of the Insolvency and Bankruptcy Code (IBC). His petition comes amid ongoing legal battles and a staggering Rs. 3,500 crore arbitral award owed to Japanese pharma major Daiichi Sankyo. With most of his assets either seized or significantly devalued due to prolonged litigation, Singh’s insolvency plea represents both a personal and financial reckoning years after the high-profile Ranbaxy deal unraveled.